Biophytis shares are trading higher. The company announced the formation of a new Scientific Advisory Board to support the advancement of its phase 2 OBA clinical study in obesity.
Portfolio Pulse from Benzinga Newsdesk
Biophytis shares are trading higher following the announcement of a new Scientific Advisory Board to support its phase 2 OBA clinical study in obesity.

April 18, 2024 | 7:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biophytis shares are experiencing an uptick after the company announced the formation of a new Scientific Advisory Board for its phase 2 OBA clinical study in obesity.
The formation of a new Scientific Advisory Board is a positive development for Biophytis, indicating a strong commitment to advancing its obesity study. This move is likely to boost investor confidence in the company's research capabilities and future prospects, leading to a short-term positive impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100